Entities related to Nantahala Capital Management, LLC
holders of more than 5% of our outstanding capital stock
Amount not stated
Purchased pre-funded warrants in the January 2024 private placement
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased pre-funded warrants in the January 2024 private placement
Purchased pre-funded warrants in the January 2024 private placement
Purchased pre-funded warrants in the April 2025 private placement
Purchased common stock and pre-funded warrants in the April 2025 private placement
Purchased common stock in the April 2025 private placement
Purchased common stock and pre-funded warrants in the September 2025 private placement
Purchased common stock and pre-funded warrants in the September 2025 private placement
Board nomination right for Nantahala; Abhinav Jain appointed as Nantahala Board Representative (Class II Director)
Purchaser in the September 2025 private placement, first closing
Board nomination right for CorMedix; Joseph Todisco appointed as CorMedix Board Representative
Right of first negotiation over an acquisition of Talphera for 60 days after the public announcement of NEPHRO CRRT topline data
Loading...
